Literature DB >> 21331691

Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.

Eriko Akaza1, Mitsuko Yuzawa, Ryusaburo Mori.   

Abstract

PURPOSE: To evaluate the visual outcomes and changes in abnormal vascular networks and polypoidal lesions of polypoidal choroidal vasculopathy (PCV) 3 years after photodynamic therapy (PDT).
METHODS: We studied 43 eyes of 43 patients with PCV for 3 years. Fundus appearance, fluorescein angiography (FA) and indocyanine green angiography (IA) findings, and visual acuity (VA) before the initial PDT were compared with those 3 months, 1 year, 2 years, and 3 years after treatment.
RESULTS: In 24 of the 43 eyes, enlargement of the abnormal vascular network continued in a manner similar to that before PDT on IA; in eight eyes, transformation into polypoidal choroidal neovascularization (CNV) with enlargement was detected; and two eyes had the appearance of classic CNV on FA. Polypoidal lesions recurred at 3 years in 33 of the 43 eyes (77%). Mean VA (logarithm of the minimum angle of resolution) of all 43 eyes decreased to below baseline at 3 years after the initial PDT. This decrease can be explained by foveal atrophy after absorption of recurrent hemorrhagic or exudative detachment.
CONCLUSION: Long-term visual outcomes were not good owing to the high frequency of recurrent polypoidal lesions, as well as enlargement and neovascular changes involving abnormal vascular networks. © Japanese Ophthalmological Society 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21331691     DOI: 10.1007/s10384-010-0886-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  29 in total

1.  Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy.

Authors:  Masami Nakajima; Mitsuko Yuzawa; Hiroyuki Shimada; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2004 May-Jun       Impact factor: 2.447

2.  Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.

Authors:  M Mauget-Faÿsse; M Quaranta-El Maftouhi; E De La Marnièrre; A Leys
Journal:  Eur J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.597

3.  Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin.

Authors:  Kaori Sayanagi; Fumi Gomi; Miki Sawa; Masahito Ohji; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

4.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation.

Authors:  H Terasaki; Y Miyake; T Suzuki; M Nakamura; T Nagasaka
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

6.  Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study.

Authors:  A Okubo; M Sameshima; A Uemura; S Kanda; N Ohba
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

7.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

8.  Clinicopathologic findings in polypoidal choroidal vasculopathy.

Authors:  Hiroyuki Nakashizuka; Masako Mitsumata; Shigekuni Okisaka; Hiroyuki Shimada; Akiyuki Kawamura; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

9.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

10.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroko Aikawa; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-04-30       Impact factor: 5.258

View more
  31 in total

1.  Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration.

Authors:  Miki Sawa; Eiji Iwata; Kohei Ishikawa; Fumi Gomi; Kohji Nishida; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2012-06-09       Impact factor: 2.447

2.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

3.  Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.

Authors:  M Inoue; A Arakawa; S Yamane; K Kadonosono
Journal:  Eye (Lond)       Date:  2013-08-23       Impact factor: 3.775

4.  Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.

Authors:  Shigeyuki Ijiri; Kazuhisa Sugiyama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-13       Impact factor: 3.117

5.  Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yukinori Sugano; Tomohiro Iida; Ichiro Maruko; Akira Ojima; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2013-02-14       Impact factor: 2.447

Review 6.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

7.  Visual prognosis of eyes with submacular hemorrhage associated with exudative age-related macular degeneration.

Authors:  Naoko Ueda-Arakawa; Akitaka Tsujikawa; Kenji Yamashiro; Sotaro Ooto; Hiroshi Tamura; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2012-10-04       Impact factor: 2.447

8.  Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Authors:  Shigeki Machida; Tomoharu Nishimura; Kunifusa Tamada; Tomomi Harada; Daijiro Kurosaka
Journal:  Doc Ophthalmol       Date:  2011-12-31       Impact factor: 2.379

9.  Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Jia Li; Jianhua Sun; Bing Li; Zheli Liu
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

10.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.